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Abstract
This study reports for the first time, to our knowledge, descriptive epidemiological data for 18 
invasive Candida isolates from Pakistan, including species identification and antifungal 
susceptibility against fluconazole, itraconazole, voriconazole, caspofungin, micafungin, 
anidulafungin and amphotericin. Risk factors for invasive candidiasis (IC) were determined for 96 
patients from Karachi, Pakistan. In adults and neonates, Candida tropicalis (38 and 36 %, 
respectively) was the most common species, followed in adults by Candida parapsilosis (17.8 %), 
Candida glabrata (15.9 %) and Candida albicans (12.3 %). C. albicans (21 %) was the second 
most common in neonates. In children, C. albicans (31.9 %), C. tropicalis (26.4 %) and C. 
parapsilosis (19.4 %) were the most common. C. albicans IC was significantly associated with 
paediatric age [crude odds ratio (COR) 3.46, 95% confidence interval (CI) 1.63–7.32]. Rare 
species made up 17.5% of the total isolates studied. Resistance to fluconazole was seen in C. 
glabrata (15.0%) and Candida krusei (100.0%). Only one isolate (C. glabrata) was resistant to all 
three echinocandins. Low MICs of fluconazole for 98% (184/188) of isolates tested support its 
continued use as an empiric therapy for IC. Non-C. albicans IC was associated with the use of β 
lactam inhibitor combinations (COR 3.16, 95% CI 1.05–9.57). Use of healthcare devices was 
documented in 85.4% of IC patients, whilst 75.0% had been admitted to special care units. 
Surprisingly, 66.7% of patients with IC were not obviously immunosuppressed. The high 
frequency of modifiable risk factors in this population indicates that candidaemia can be reduced 
with stringent antibiotic and infection control measures. These data will be useful for empiric 
selection of antifungals in Karachi, and contribute to global assessments of antifungal resistance.
INTRODUCTION
Invasive candidiasis (IC) is a severe illness with a high mortality and increasing overall cost 
of management (Colombo et al., 2006; Hassan et al., 2009; Horn et al., 2009; Pfaller et al., 
2011d). Advances in medical technology and therapeutics have resulted in increasing 
numbers of invasive fungal infections including IC (Diaz & Fell, 2004). Individuals 
considered at greatest risk of IC are premature infants, patients receiving broad-spectrum 
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antibiotics or anti-cancer chemotherapy (Picazo et al., 2008) and those with 
immunodeficiencies such as haematopoietic stem-cell transplant or solid-organ transplant 
recipients, profound neutropenia or diabetes (Kontoyiannis et al., 2010; Pappas et al., 2010).
Globally, Candida albicans is the most frequently reported species; however, the emergence 
of non-C. albicans Candida species with resistance to fluconazole is of concern, highlighted 
by recent surveillance data (Pfaller et al., 2011d). As inappropriate initial therapy for IC can 
result in an adverse outcome, accurate identification of the species responsible for IC and 
knowledge of their corresponding susceptibility patterns are essential. It is also important to 
recognize populations at greater risk of IC in the healthcare setting. In the absence of a 
national surveillance system for IC in Pakistan, laboratory data are epidemiologically useful 
to identify susceptible patient populations, monitor trends and detect emerging resistance. 
Most of the clinical laboratories in Pakistan rely on phenotypic identification methods to 
report Candida species; however, current genotypic methods of identification are considered 
more reliable, especially for the less common species (Deak et al., 2010; Wang et al., 2008).
In this study, we determined the spectrum of invasive Candida isolates in samples collected 
from major cities of Pakistan, confirmed their identification to the species level with 
molecular methods and determined their susceptibility patterns. We also analysed risk 




The study was conducted in the clinical laboratory of the Aga Khan University Hospital 
(AKUH), Karachi, Pakistan. The laboratory has a national specimen collection network with 
more than 175 collection points in major cities and towns across the country. Samples are 
processed in the clinical laboratory based in Karachi. The laboratory data were collected 
from nine major cities in Pakistan, the majority from Karachi.
Definitions
IC was defined as the isolation of Candida species from normally sterile specimens, such as 
blood, cerebrospinal fluid, peritoneal fluid, pleural fluid, synovial fluid and bile, and from 
the tips of central venous catheters and from ventriculoperitoneal shunts. Patients were 
considered children if they were ≤14 years, and neonates if they were <30 days. Isolation of 
the same Candida species within 15 days was considered a single episode of IC. Sepsis was 
defined as presence of hypotension (systolic blood pressure <90 mm Hg or the need for 
inotropes), temperature <36 or >38 °C and a white blood cell count of <4000 or >10 000 
mm−3. Admission to adult, paediatric or neonatal intensive care units was considered 
‘special care stay’. Nosocomial infections were those acquired after >48 h of admission to, 
or within 90 days of discharge from, a healthcare facility. A central line-associated 
bloodstream infection (CLABSI) was considered if there was no other source of 
bloodstream infection except a central venous line. A β-lactam inhibitor combination (BLIC) 
was cephalosporin or penicillins combined with tazobactam, clavulanic acid or sulbactam. 
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Patients on dialysis received either peritoneal or haemodialysis. Neutrophilia was defined as 
>70 % neutrophils on a peripheral blood smear, whilst neutropenia was defined as an 
absolute neutrophil count of <1000 mm−3. ‘Prior antifungal use’ was the administration of 
fluconazole, voriconazole, itraconazole or amphotericin B at least 24 h before collection of 
the specimen yielding Candida species. Healthcare devices included central venous lines 
[femoral, jugular or subclavian central venous catheters, haemodialysis catheters, 
peripherally inserted central catheter lines, portacath or Hickman lines], permanent or 
transient pacemakers, ventilators, abdominal or chest drains, peritoneal dialysis catheters, 
percutaneous nephrostomy tubes, suprapubic catheters, percutaneous endoscopic 
gastrostomy tubes, pancreatic duct stents, endoventricular drains, ventriculoperitoneal shunts 
and orthopaedic implants. ‘Complicated intra-abdominal infection’ was defined as 
abdominal infection spreading beyond the hollow viscus into the peritoneal cavity, resulting 
in peritonitis or intra-abdominal abscess. Community-acquired or healthcare-associated 
pneumonia or urinary tract infections were all included in ‘pneumonia’ or ‘urinary tract 
infection’, respectively. Total parenteral nutrition was the administration of amino acids and 
lipids via the intravenous route when enteral feeding was not possible or inadequate. 
‘Immunosuppressed status’ was when the patient was receiving steroids, cyclosporine, 
azathioprine or anti-cancer chemotherapy, or was neutropenic, or was a cancer or transplant 
patient.
Risk factor study
Medical records of 96/183 patients (118/207 isolates) registered with AKUH were retrieved 
for a retrospective clinical data review. Risk factors, underlying disease and the course of 
clinical illness were recorded.
Yeast identification
During the study period (January 2006 to May 2009), 207 sterile specimens from 180 
patients yielded Candida species. After excluding duplicates from the same episode of 
candidiasis, 188 isolates were included. Five patients had candidaemia with multiple 
species, whilst two had recurrence of IC with the same species. The specimens were 166 
blood cultures, 15 sterile fluids (seven peritoneal, three pleural, three cerebrospinal fluid and 
two others), six central catheter tips and one ventricular shunt end tip. The geographical 
origin of these isolates was as follows: 134 were from AKUH, 34 were from other 
healthcare facilities in Karachi and 20 were from additional cities in Pakistan (seven from 
Lahore, four from Multan, three from Hyderabad, two from Quetta and one each from 
Peshawar, Rawalpindi, Bahawalpur and Rahimyar Khan). Species identification was based 
on conventional phenotypic characteristics: production of a germ tube, morphology on BBL 
BiGGY Agar (BD), growth with cycloheximide, urease production, morphology on 
cornmeal/Tween 80 agar and the identification profile generated using API 20C AUX 
(bioMe´rieux). Isolates were stored in glycerol phosphate buffer at −80 °C. Their 
identification was also confirmed using either a Luminex multianalyte profiling assay with 
the ITS2 target or DNA sequencing as described previously by Das et al. (2006) and Deak et 
al. (2010). Agreement between phenotypic and molecular identification was >90 % for 
common species such as C. albicans, Candida tropicalis and Candida parapsilosis.
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Antifungal susceptibility testing was performed by broth microdilution with fluconazole, 
itraconazole, voriconazole, posaconazole, anidulafungin, caspofungin and micafungin as 
described by the Clinical and Laboratory Standards Institute (CLSI, 2008) using frozen 
RPMI microbroth trays custom manufactured by TREK Diagnostics. Results were read 
visually after 24 h of incubation as the lowest concentration of drug that caused a significant 
decrease in growth compared with the control well. Recently approved although not yet 
published CLSI 24 h resistance breakpoints for fluconazole, voriconazole and the 
echinocandins were used (CLSI, 2008; Pfaller et al., 2010a, 2011a, c). C. albicans, C. 
tropicalis and C. parapsilosis with MICs ≥8 µg ml−1 and C. glabrata with an MIC ≥64 µg 
ml−1 were considered resistant to fluconazole, whilst Candida krusei was considered 
intrinsically resistant to fluconazole. C. albicans, C. tropicalis and C. parapsilosis with 
MICs ≥1 mg ml21 were considered resistant to voriconazole. C. albicans, C. tropicalis and 
C. krusei with MICs ≥1 µg ml−1 were considered resistant to caspofungin, micafungin and 
anidulafungin; C. para-psilosis with MICs ≥8 µg ml−1 was considered resistant to 
caspofungin, micafungin and anidulafungin; Candida glabrata with MICs ≥0.5 µg ml−1 was 
considered resistant to caspofungin and anidulafungin and with an MIC ≥0.25 µg ml−1 was 
resistant to micafungin. In the absence of clinical breakpoints, epidemiological cut-off 
values (ECVs) were used to interpret MICs as those conforming to wild-type or non-wild-
type for a particular antifungal agent against a specific species. ECVs for fluconazole were 8 
µg ml−1 for Candida guilliermondii, 4 µg ml−1 for Candida pelliculosa, 2 µg ml−1 for 
Candida lusitaniae and Candida orthopsilosis and 1 µg ml−1 for Candida kefyr. ECVs for 
voriconazole were 0.25 µg ml−1 for C. guilliermondii and C. pelliculosa, 0.03 µg ml−1 for C. 
lusitaniae, 0.06 µg ml−1 C. orthopsilosis and 0.015 µg ml−1 for C. kefyr (Pfaller et al., 
2011b). Similarly, ECVs of anidulafungin were 4 µg ml−1 for C. guilliermondii, 2 µg ml−1 
for C. lusitaniae and C. orthopsilosis, and 0.25 µg ml−1 for C. kefyr, and those for 
caspofungin were 2 µg ml−1 for C. guilliermondii, 1 µg ml−1 for C. lusitaniae, 0.5 µg ml−1 
for C. orthopsilosis, 0.12 µg ml−1 for C. pelliculosa and 0.03 µg ml−1 for C. kefyr (Pfaller et 
al., 2011b). ECVs for micafungin were 2 µg ml−1 for C. guilliermondii, 1 µg ml−1 for C. 
orthopsilosis, 0.5 µg ml−1 for C. lusitaniae and 0.12 µg ml−1 for C. kefyr (Pfaller et al., 
2011b). Amphotericin B MICs were obtained by Etest on RPMI agar by making a lawn with 
a 0.5 McFarland standard inoculum and incubating it for 24 h at 35 °C. The MICs of 
amphotericin and itraconazole were also interpreted according to ECVs (Pfaller et al., 2012). 
For amphotericin, the ECV for C. albicans, C. tropicalis, C. parapsilosis, C. glabrata, C. 
krusei, C. guilliermondii and C. lusitaniae was 2 µg ml−1. For itraconazole, ECVs were 0.12 
µg ml−1 for C. albicans, 0.5 µg ml−1 for C. parapsilosis, C. tropicalis and C. lusitaniae, 1 µg 
ml−1 for C. krusei and C. guilliermondii and 2 µg ml−1 for C. glabrata.
Statistical analysis
Data were entered in Microsoft Access (2007) and transferred to SPSS version 19.0 for 
analysis. The frequencies of Candida species and their susceptibility profile and risk factors 
were determined. Patient characteristics associated with Candida species were evaluated 
using a χ2 test. The crude odds ratio (COR) and 95 % confidence interval (CI) were 
calculated for variables found to have significant associations.
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Demographics, clinical characteristics and risk factors
A cross-sectional in vitro observational study was performed to determine the species 
spectrum in IC, together with the susceptibility profiles of the isolates and the risk factors 
associated with the disease. The demographics of 180 patients revealed a male/female ratio 
of 1.47. The mean age of 67 paediatric patients was 1.9 years (0 days–14 years), with 33 
neonates. The mean age of 113 adults was 47.4 years (15–96 years), and 83 (73.5 %) of 
these were <65 years of age. The crude mortality rate was 52.1 %.
Further clinical information was available on 96 patients seen at AKUH (Tables 1 and 2). In 
this group, C. albicans IC was significantly associated with children and neonates (COR 
3.46, 95% CI 1.63–7.32) and not with adults (COR 0.29, CI 0.14–0.61), whilst C. glabrata 
was associated with adults (COR 6.44, 95 % CI 1.45–28.69) and not with the paediatric 
group (COR 0.16, 95 % CI 0.04–0.69). However, the number of neonates with available 
clinical information was too small to compare separately for the presence of other risk 
factors.
Among these patients, overall use of carbapenems and BLICs was documented in 53 and 
46% of cases, respectively. Paediatric IC, including neonates, was significantly associated 
with increased use of cephalosporins (COR 4.14, 95 % CI 1.52–11.26) and decreased use of 
BLICs (COR 0.13, 95% CI 0.35–0.47) and vancomycin (COR 0.33, 95 % CI 0.11–0.98) 
compared with adults.
In 91.6 % of cases, IC was acquired nosocomially. Use of healthcare devices of central 
venous catheters, ventilators and abdominal and pleural cavity drains was documented in 
85.4 % of patients with IC, whilst 75.0 % of these individuals had spent time in special/
intensive care units. Administration of total parenteral nutrition was also found to be 
significantly higher among children and neonates (COR 3.58, 95 % CI 1.25–10.23). Using 
the study criteria, 66.7 % of the study population were not overtly immunosuppressed.
Table 2 shows the association of risk factors with isolation of the four most common 
Candida species. IC with C. tropicalis was significantly associated with the presence of 
chronic liver disease (COR 5.16, 95 % CI 1.19–22.33), sepsis (COR 3.71, 95 % CI 1.16–
11.92) and the need for dialysis (COR 4.21, 95 % CI 1.42–12.55). Candidaemia with C. 
albicans was seen less frequently in cases where there was use of BLICs (COR 0.32, 95 % 
CI 0.10–0.96). Isolation of C. parapsilosis was higher with established CLABSI (COR 4.53, 
95% CI 1.35–15.25) and C. glabrata from diabetic patients (COR 5.08, 95 % CI 1.21–
21.34). The risk of isolation of C. glabrata was found to be low with the use of carbapenem 
antibiotics (COR 0.18, 95 % CI 0.03–0.95).
Species distribution
The most commonly isolated Candida species overall was C. tropicalis (32.5 %), followed 
by C. albicans (20.2 %) and C. parapsilosis (15.0 %). Rare species including C. 
guilliermondii, C. metapsilosis, C. orthopsilosis, C. viswanathii, C. pelliculosa, C. utilis, C. 
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fabianii, C. rugosa, C. kefyr and two novel Candida species comprised 17.5 % of total IC 
isolates (Tables 3 and 4).
Adults, neonates and children displayed different species distribution profiles (Fig. 1). In 
adults and neonates, C. tropicalis (38 and 36 %, respectively) was common, whilst in 
children the predominant isolate was C. albicans (44 %). The isolation rates of C. glabrata 
were minimal (6 %) in neonates and 0 % in children.
Antifungal susceptibility
Table 3 shows the MIC50 and MIC90 values, the MIC range and the percentage of resistant 
isolates. In general, most isolates were susceptible to the drugs tested. Resistance to 
fluconazole was seen in C. glabrata (15 %) and C. krusei (100 %). For the rare Candida 
species, the MIC90 values of fluconazole were ≤4 µg ml−1; however, one C. pelliculosa 
strain showed non-wild-type behaviour in respect to fluconazole with an MIC of 8 µg ml−1 
(Tables 3 and 4). Non-wild-type behaviour in regard to itraconazole was seen among C. 
albicans (23.7 %), C. tropicalis (19.7 %) and C. glabrata (10.0 %) isolates (Table 3). Only 
one C. glabrata isolate was resistant to voriconazole. All isolates displayed amphotericin B 
MICs of <1.0 µg ml−1, well below the ECV of 2.0 µg ml−1. All isolates except one C. 
glabrata strain (caspofungin MIC of 0.5 µg ml−1, anidulafungin MIC of 1.0 µg ml−1 and 
micafungin MIC of 0.5 µg ml−1) were susceptible to echinocandins, as shown in Table 3.
DISCUSSION
This assessment of the epidemiology of IC in Pakistan showed C. tropicalis to be the species 
isolated most frequently from adult and neonatal IC patients (33 % of cases). This finding 
contrasts with reports from the USA, Europe, South America and the Far East, which have 
reported C. albicans as the most common species (Colombo et al., 2006; Falagas et al., 
2010; Odds et al., 2007), with the most frequent non-C. albicans species being either C. 
parapsilosis in Southern Europe and South America or C. glabrata in the USA and UK. We 
found C. albicans to be the fourth most common Candida species among adult IC pathogens 
in Pakistan after C. tropicalis, C parapsilosis and C. glabrata. Our results support regional 
data from India showing C. tropicalis to be the most prevalent species in hospital-based 
surveys (Falagas et al., 2010; Kothari & Sagar, 2009). Studies from Singapore, Taiwan and 
Brazil have also reported C. tropicalis as the most common non-C. albicans species (Liu et 
al., 2010; Pereira et al., 2010; Tan et al., 2010). C. tropicalis has been reported as an 
emerging pathogen in hospital-based surveys of IC in Singapore and Hong Kong (Chai et 
al., 2007; Yap et al., 2009). Compared with data from the ARTEMIS disc diffusion 
surveillance, our isolation rates of C. tropicalis and C. guilliermondii were much higher than 
those reported from Africa, the Middle East and Asia Pacific (Pfaller et al., 2010a). The 
emergence of C. tropicalis causing IC in Indian studies has been attributed to increased 
fluconazole resistance and virulence, as portrayed by an increased rate of growth and the 
production of proteinases facilitating invasion (Basu et al., 2011; Kothavade et al., 2010). 
We did not find overt fluconazole resistance in Pakistani isolates of C. tropicalis, but the 
pathogenicity of this species requires further study. An association of C. tropicalis 
fungaemia with severity indicators such as sepsis (COR 3.71, 95 % CI 1.16–11.92; Table 2) 
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and the need for dialysis (COR 4.21, 95 % CI 1.42–12.55; Table 2) supports our theory of 
increasing virulence in this species. It was also found more frequently in patients suffering 
from chronic liver disease (COR 5.16, 95 % CI 1.19–22.33), a result not particularly found 
in other studies but which possibly reflects increased C. tropicalis gastrointestinal carriage, 
leading to candidaemia in such patients (Kusne et al., 1994; Nucci & Colombo, 2007).
Our data showed a clear distinction between the spectrum of adult, neonatal and paediatric 
(age >1 month) IC pathogens, with C. albicans, C. tropicalis and C. parapsilosis being the 
three main paediatric IC agents. The age distribution of species in an international SENTRY 
survey for antifungal resistance showed C. albicans as the most common species isolated, 
irrespective of age group (Pfaller et al., 2010b). Conversely, our data showed a clear 
predominance of C. albicans (44 %) only in children, whilst in adults and neonates ~70 % of 
IC was caused by species other than C. albicans. This species distribution among the 
paediatric age group is supported by other reports published on the epidemiology of 
candidiasis in children (Ariff et al., 2011; Zaoutis, 2010). Differences in the epidemiology of 
IC in adults and children suggest that pressures, such as the spectrum of antibiotics used or 
gut colonization in Asian individuals, influencing the selection of non-C. albicans species in 
adults are not found as frequently in children. Although the distribution of species among 
neonates and adults appeared similar compared to that among children >1 month of age, a 
lack of clinical information unfortunately limited our ability to assess statistically the risk 
factors for neonates separately. Use of vancomycin and BLICs, an established risk factor for 
non-C. albicans species (Lin et al., 2005) and also significantly associated with non-C. 
albicans IC in this study (COR 0.32, 95 % CI 0.10–0.96; Table 2), was found to be 
significantly low at 22.7 and 13.6% in children and neonates, respectively (COR 0.33, 95 % 
CI 0.11–0.98 and COR 0.13, 95 % CI 0.35–0.47, respectively; Table 1).
The study of risk factors in our patients suggested that IC was mainly a nosocomial infection 
(91.6 % of cases), with most patients requiring intensive care and broad-spectrum parenteral 
antibiotic therapy. Although AKUH is a tertiary care hospital and a bone-marrow transplant 
centre, more than two thirds of the patients with IC in AKUH were without obvious 
immunocompromised status: only 9.4 % were neutropenic. Most studies of risk factors 
associated with IC are either hospital-based, intensive care unit or specific unit surveys (e.g. 
burns unit, transplant registry, etc.). A study from Greece that compared risk factors in 
immunocompetent and immunocompromised hosts (Dimopoulos et al., 2007) determined 
the risk factors to be the use of central venous catheters and urinary catheters, prolonged 
hospital stay and intra-abdominal infections in immunocompetent hosts and haematopoietic 
stem-cell transplant recipients, and neutropenia in immunocompromised patients. In 
hospital-based surveys, stay in special care units and infections with other nosocomial 
organisms were associated with high mortality, whilst central intravascular catheters and 
previous azole therapy were significantly associated with C. parapsilosis and C. krusei, 
respectively (Dimopoulos et al., 2007; Erdem et al., 2010; Ortega et al., 2011). Our study 
also found C. parapsilosis to be significantly associated with CLABSI (COR 4.53, 95 % CI 
1.35–15.25; Table 2). Recently, the Infectious Disease Society of America has published 
guidelines for the prevention of intravascular catheter-related bloodstream infections, 
emphasizing barrier and aseptic precautions, clean sites of insertion and timely removal of 
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central lines (O’Grady et al., 2011). In our patients, the high rates of modifiable risk factors, 
such as the use of central lines, staying in a special care unit and the use of broad-spectrum 
antibiotics, suggest that a significant proportion of IC may be preventable. Thus, adhering to 
the central line bundle and good antibiotic monitoring may effectively reduce IC rates, 
highlighting the importance of infection control.
The association of C. glabrata with diabetes is well established (Bader et al., 2004); 
however, the association of carbapenem use with a decreased risk of C. glabrata infection 
needs further investigation, as this may be due to the small sample size.
C. tropicalis, C. albicans, C. parapsilosis, C. glabrata and C. krusei comprised only 83 % of 
this collection, although they generally comprise >90 % of most surveillance collections 
(Pfaller & Diekema, 2007). Higher rates of recovery of uncommon species such as C. 
guilliermondii, C. lusitaniae and other rare species (17.5 % of the total IC isolates) in this 
study suggest that investment in molecular yeast identification methodology would be 
worthwhile. However, the phenotypic identification methods employed had good species 
agreement rates with molecular identification, with the exception of C. guilliermondii and 
rare Candida species, and may be used until molecular identification becomes more 
available in this country.
Resistance to azole antifungals, particularly fluconazole, in certain species has been 
increasing in recent years in the USA and Europe. Studies from Europe, South America and 
the USA reported low resistance rates to fluconazole and itraconazole before 2005 (Pfaller 
& Diekema, 2007), but data from the latter half of the decade show emerging resistance not 
only against azoles but also against echinocandins in nosocomial isolates (Pfaller et al., 
2011d). Our isolates did not manifest high rates of fluconazole resistance except among C. 
glabrata and C. krusei isolates.
All Candida species in our study had low amphotericin B MICs, reinforcing the reliability of 
amphotericin B as an empirical choice. Although all our isolates were echinocandin naïve, 
as caspofungin has only recently become available in Pakistan, one C. glabrata isolate 
showed resistance to echinocandins, suggesting that selection pressures may play a role in 
the future as echinocandin use increases. Regardless of this, where cost is not an issue and 
C. glabrata and C. krusei have been isolated, echinocandins can be considered good choices 
for directed antifungal therapy in Pakistan. There are, however, reports from other parts of 
the world of resistance among nosocomial C. glabrata isolates against echinocandins (Pfaller 
et al., 2011d; Zimbeck et al., 2010).
With the infrequent isolation of C. glabrata and C. krusei and fluconazole resistance rates of 
0 % among other Candida species in this study, fluconazole may be considered a good 
empiric choice. Good antibiotic monitoring could save the use of echinocandins for 
confirmed cases of C. glabrata and C. krusei, keeping the cost of therapy and antifungal 
exposure minimal, as the costs attributable to candidaemia are already high (Hassan et al., 
2009). As the clinical use of antifungals increases we may see the emergence of resistance, 
and accurate identification to the species level as well as routine antifungal susceptibility 
testing are likely to have greater implications. There is evidence of changes in epidemiology 
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and increasing rates of azole resistance in developed countries, which advocates continuing 
surveillance for species and the antifungal susceptibility spectrum (Falagas et al., 2010; 
Pfaller et al., 2011d).
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Distribution of species based on the age of IC patients in this study. Black bars, neonates; 
dark grey bars, children; light grey bars, adults.
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